-
公开(公告)号:US20180274033A1
公开(公告)日:2018-09-27
申请号:US15928939
申请日:2018-03-22
申请人: Mariano A. Garcia-Blanco , Gaddiel Galarza-Munoz , Simon G. Gregory , Farren B.S. Briggs , Lisa F. Barcellos , Shelton S. Bradrick , Irina Evsyukova , Dennis C. Ko
发明人: Mariano A. Garcia-Blanco , Gaddiel Galarza-Munoz , Simon G. Gregory , Farren B.S. Briggs , Lisa F. Barcellos , Shelton S. Bradrick , Irina Evsyukova , Dennis C. Ko
IPC分类号: C12Q1/6883 , C12Q1/34 , C12Q1/6806
CPC分类号: C12Q1/6883 , C12Q1/34 , C12Q1/6806 , C12Q1/683 , C12Q1/6851 , C12Q1/686 , C12Q2600/156 , C12Y306/04013
摘要: The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.
-
2.
公开(公告)号:US20210024938A1
公开(公告)日:2021-01-28
申请号:US17027467
申请日:2020-09-21
IPC分类号: C12N15/113 , A61K31/7088 , A61K45/06
摘要: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).
-